XT 150

Drug Profile

XT 150

Alternative Names: XT 101; XT-150

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xalud Therapeutics
  • Class Non-opioid analgesics
  • Mechanism of Action Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Phase I Osteoarthritis
  • Preclinical Neuropathic pain
  • Research Amyotrophic lateral sclerosis; Multiple sclerosis

Most Recent Events

  • 08 Jun 2018 Phase-I clinical trials in Osteoarthritis in USA (Parenteral) (NCT03477487)
  • 04 Apr 2018 Xalud Therapeutics plans a phase I trial for Osteoarthritis in USA, in June 2018 (NCT03477487)
  • 04 Apr 2018 XT 150. is available for licensing as of 04 Apr 2018. http://www.xaludthera.com/contact-us/ (Xalud Therapeutics website, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top